[Influencing the fibrinolytic activity by antithrombotics in patients with atherosclerosis].
In 106 atherosclerotic patients receiving an anticoagulant therapy and 91 patients receiving acetylsalicylic acid, fibrinogen and fibrin degradation products were determined as well as euglobulin lysis before and after venous occlusion. Platelet function data and thromboxane (TXB2) were also determined. Since "moderate" anticoagulant therapy with thromboplastin time values 26-40% results in deteriorated fibrinolysis data, anticoagulant therapy is strictly to remain within the therapeutic range of 15-20% up to 25% thromboplastin time at maximum. Treatment with acetylsalicylic acid proved useful on condition that the required dose was determined individually. This type of treatment will then be able to reduce the thromboxane level and positively influence the fibrinolytic potential.
Norden
C
C
Zentralinstitut für Herz-Kreislauf-Forschung, Akademie der Wissenschaften, DDR Berlin-Buch.
Reimann
H
H
Grunow
G
G
Misselwitz
F
F
Taube
C
C
Heine
H
H
D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D001241:Aspirin / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D005342:Fibrinolysis; D006801:Humans; D010979:Platelet Function Tests
D000925:Anticoagulants; D001241:Aspirin
Die Beeinflussung der Fibrinolysekapazität durch Antithrombotika bei Patienten mit Arteriosklerose.